Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, et al. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019;14(6):e0218660.

Vossoughi S, Gorlin J, Kessler DA, Hillyer CD, Van Buren NL, Jimenez A, et al. Ten years of TRALI mitigation: measuring our progress. Transfusion. 2019;59(8):2567-2574.

Son DH, Doan KV, Yang DJ, Sun JS, Kim SK, Kang N, et al. FoxO1 regulates leptin-induced mood behavior by targeting tyrosine hydroxylase. Metabolism. 2019;91:43-52.

Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, et al. The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3. Cancer Res. 2019;79(12):3076-3087.

Nouizi F, Kwong TC, Ruiz J, Cho J, Chan Y-, Ikemura K, et al. A thermo-sensitive fluorescent agent based method for excitation light leakage rejection for fluorescence molecular tomography. Phys Med Biol. 2019;64(3):035007.

Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, et al. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv. 2019;1(1):vdz004.

Kyriakides K, Selkin G, Selkin B, Iwenofu H, Magro CM. Chronic Fibrosing Vasculitis in the Setting of Still Disease. J Clin Rheumatol. 2019;25(7):e127-e130.

Hogan M, Geyer JT, Bussel JB. Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. Am J Hematol. 2019;94(7):E196-E198.

Dall'Acqua S, Grabnar I, Verardo R, Klaric E, Marchionni L, Luidy-Imada E, et al. Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. Phytomedicine. 2019;65:153090.

Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, et al. TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. Lung Cancer (Auckl). 2019;10:81-86.